2
|
Iamartino L, Elajnaf T, Gall K, David J, Manhardt T, Heffeter P, Grusch M, Derdak S, Baumgartner-Parzer S, Schepelmann M, Kallay E. Effects of pharmacological calcimimetics on colorectal cancer cells over-expressing the human calcium-sensing receptor. BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH 2020; 1867:118836. [PMID: 32861746 DOI: 10.1016/j.bbamcr.2020.118836] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Revised: 08/21/2020] [Accepted: 08/25/2020] [Indexed: 02/06/2023]
Abstract
The calcium-sensing receptor (CaSR) is a ubiquitously expressed multifunctional G protein-coupled receptor. Several studies reported that the CaSR plays an anti-inflammatory and anti-tumorigenic role in the intestine, and that it is down-regulated during colorectal carcinogenesis. We hypothesized that positive allosteric CaSR modulators (type II calcimimetics) selectively targeting the intestinal cells could be used for the treatment of intestinal pathologies. Therefore, the aim of this study was to determine the effect of pharmacological stimulation of CaSR on gene expression in vitro and on tumor growth in vivo. We stably transduced two colon cancer cell lines (HT29 and Caco2) with lentiviral vectors containing either the CaSR fused to GFP or GFP only. Using RNA sequencing, RT-qPCR experiments and ELISA, we determined that CaSR over-expression itself had generally little effect on gene expression in these cells. However, treatment with 1 μM of the calcimimetic NPS R-568 increased the expression of pro-inflammatory factors such as IL-23α and IL-8 and reduced the transcription of various differentiation markers in the cells over-expressing the CaSR. In vivo, neither the presence of the CaSR nor p.o. treatment of the animals with the calcimimetic cinacalcet affected tumor growth, tumor cell proliferation or tumor vascularization of murine HT29 xenografts. In summary, CaSR stimulation in CaSR over-expressing cells enhanced the expression of inflammatory markers in vitro, but was not able to repress colorectal cancer tumorigenicity in vivo. These findings suggest potential pro-inflammatory effects of the CaSR and type II calcimimetics in the intestine.
Collapse
Affiliation(s)
- Luca Iamartino
- Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute for Pathophysiology and Allergy Research, Währinger Gürtel 18-20, 1090 Vienna, Austria
| | - Taha Elajnaf
- Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute for Pathophysiology and Allergy Research, Währinger Gürtel 18-20, 1090 Vienna, Austria
| | - Katharina Gall
- Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute for Pathophysiology and Allergy Research, Währinger Gürtel 18-20, 1090 Vienna, Austria
| | - Jacquelina David
- Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute for Pathophysiology and Allergy Research, Währinger Gürtel 18-20, 1090 Vienna, Austria
| | - Teresa Manhardt
- Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute for Pathophysiology and Allergy Research, Währinger Gürtel 18-20, 1090 Vienna, Austria
| | - Petra Heffeter
- Medical University of Vienna, Institute of Cancer Research and Comprehensive Cancer Center, Borschkegasse 8a, 1090 Vienna, Austria
| | - Michael Grusch
- Medical University of Vienna, Institute of Cancer Research and Comprehensive Cancer Center, Borschkegasse 8a, 1090 Vienna, Austria
| | - Sophia Derdak
- Medical University of Vienna, Core Facilities, Lazarettgasse 14, 1090 Vienna, Austria
| | - Sabina Baumgartner-Parzer
- Medical University of Vienna, Department of Internal Medicine III, Währinger Gürtel 18-20, 1090 Vienna, Austria
| | - Martin Schepelmann
- Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute for Pathophysiology and Allergy Research, Währinger Gürtel 18-20, 1090 Vienna, Austria
| | - Enikö Kallay
- Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute for Pathophysiology and Allergy Research, Währinger Gürtel 18-20, 1090 Vienna, Austria.
| |
Collapse
|
8
|
Graham LA, Padmanabhan S, Fraser NJ, Kumar S, Bates JM, Raffi HS, Welsh P, Beattie W, Hao S, Leh S, Hultstrom M, Ferreri NR, Dominiczak AF, Graham D, McBride MW. Validation of Uromodulin as a Candidate Gene for Human Essential Hypertension. Hypertension 2014; 63:551-8. [DOI: 10.1161/hypertensionaha.113.01423] [Citation(s) in RCA: 88] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
A recent genome-wide association study identified a locus on chromosome 16 in the promoter region of the uromodulin (
UMOD
) gene that is associated with hypertension. Here, we examined the hypertension signal with functional studies in Umod knockout (KO) mice. Systolic blood pressure was significantly lower in KO versus wild-type (WT) mice under basal conditions (KO: 116.6±0.3 mm Hg versus WT: 136.2±0.4 mm Hg;
P
<0.0001). Administration of 2% NaCl did not alter systolic blood pressure in KO mice, whereas it increased in WT mice by ≈33%,
P
<0.001. The average 24-hour urinary sodium excretion in the KO was greater than that of WT mice (
P
<0.001). Chronic renal function curves demonstrate a leftward shift in KO mice, suggesting that the relationship between UMOD and blood pressure is affected by sodium. Creatinine clearance was increased during salt loading with 2% NaCl in the KO mice, leading to augmented filtered Na
+
excretion and further Na
+
loss. The difference in sodium uptake that exists between WT and KO strains was explored at the molecular level. Urinary tumor necrosis factor-α levels were significantly higher in KO mice compared with WT mice (
P
<0.0001). Stimulation of primary thick ascending limb of the loop of Henle cells with exogenous tumor necrosis factor-α caused a reduction in NKCC2A expression (
P
<0.001) with a concurrent rise in the levels of UMOD mRNA (
P
<0.001). Collectively, we demonstrate that UMOD regulates sodium uptake in the thick ascending limb of the loop of Henle by modulating the effect of tumor necrosis factor-α on NKCC2A expression, making UMOD an important determinant of blood pressure control.
Collapse
Affiliation(s)
- Lesley A. Graham
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Sandosh Padmanabhan
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Niall J. Fraser
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Satish Kumar
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - James M. Bates
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Hajamohideen S. Raffi
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Paul Welsh
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Wendy Beattie
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Shoujin Hao
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Sabine Leh
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Michael Hultstrom
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Nicholas R. Ferreri
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Anna F. Dominiczak
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Delyth Graham
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Martin W. McBride
- From the Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (L.A.G., S.P., N.J.F., P.W., W.B., A.F.D., D.G., M.W.M.); Department of Medicine, University of Oklahoma Health Sciences Centre and Veterans Affairs Medical Center, Oklahoma City (S.K., J.M.B., H.S.R.); Department of Pharmacology, New York Medical College, Valhalla (S.H., N.R.F.); Department of Pathology, Haukeland University Hospital, Bergen, Norway
| |
Collapse
|